Vol 8, No 2 (2022)
Review paper
Published online: 2022-06-23

open access

Page views 4156
Article views/downloads 356
Get Citation

Connect on Social Media

Connect on Social Media

Interstitial lung disease in the course of systemic connective tissue diseases: A common problem for rheumatologists and pulmonologists

Zuzanna Gogulska1, Żaneta Smoleńska1, Amelia Szymanowska-Narloch2, Zbigniew Zdrojewski1
Rheumatology Forum 2022;8(2):77-83.

Abstract

Interstitial lung disease is a common and dangerous complication of many rheumatic diseases. Progress over the last several years has increased diagnostic capabilities, led to emergence of new therapeutic options and, above all, resulted in deeper awareness of the severity of the problem. Interstitial diseases are a heterogeneous group differentiated through histopathological and imaging examinations. Prognosis and recommended therapy depend not only on the form of the interstitial disease, but also largely on its underlying rheumatic disease. The aim of this article is to present the pathology that is the interstitial lung disease and the current knowledge on its treatment.

Article available in PDF format

View PDF Download PDF file

References

  1. Kaul B, Cottin V, Collard HR, et al. Variability in Global Prevalence of Interstitial Lung Disease. Front Med (Lausanne). 2021; 8: 751181.
  2. Dellaripa PF. Interstitial lung disease in the connective tissue diseases; a paradigm shift in diagnosis and treatment. Clin Immunol. 2018; 186: 71–73.
  3. Troy LK, Corte TJ. The Physiology of Interstitial Lung Disease. In: Janes S. ed. Encycloedia of Resiratory Medicine. 2nd Edition. Elsevier 2022: 10–22.
  4. Vivero M, Padera RF. Histopathology of lung disease in the connective tissue diseases. Rheum Dis Clin North Am. 2015; 41(2): 197–211.
  5. Kwon KY. Pathological interpretation of connective tissue disease-associated lung diseases. Yeungnam Univ J Med. 2019; 36(1): 8–15.
  6. Nayfeh AS, Chippa V, Moore DR. Nonspecific Interstitial Pneumonitis. StatPearls, Treasure Island 2022.
  7. Hino T, Lee K, Yoo H, et al. Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP). European Journal of Radiology Open. 2021; 8: 100336.
  8. Renzoni E, Poletti V, Mackintosh J. Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia? The Lancet. 2021; 398(10309): 1437–1449.
  9. Munchel JK, Shea BS. Diagnosis and Management of Idiopathic Pulmonary Fibrosis. R I Med J. 2021; 104(7): 26–29.
  10. Chung JH, Montner SM, Thirkateh P, et al. Computed Tomography Findings Suggestive of Connective Tissue Disease in the Setting of Usual Interstitial Pneumonia. J Comput Assist Tomogr. 2021; 45(5): 776–781.
  11. Cottin V, Cordier JF. Organizing Pneumonia. Clinical Respiratory Medicine. 2012: 629–636.
  12. Cho YH, Chae EJ, Song JW, et al. Chest CT imaging features for prediction of treatment response in cryptogenic and connective tissue disease-related organizing pneumonia. Eur Radiol. 2020; 30(5): 2722–2730.
  13. Louza GF, Nobre LF, Mançano AD, et al. Lymphocytic interstitial pneumonia: computed tomography findings in 36 patients. Radiol Bras. 2020; 53(5): 287–292.
  14. Ichikado K. High-resolution computed tomography findings of acute respiratory distress syndrome, acute interstitial pneumonia, and acute exacerbation of idiopathic pulmonary fibrosis. Semin Ultrasound CT MR. 2014; 35(1): 39–46.
  15. Panagopoulos P, Goules A, Hoffmann-Vold AM, et al. Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 2021; 13: 1759720X211037519.
  16. Bendstrup E, Møller J, Kronborg-White S, et al. Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians. J Clin Med. 2019; 8(12).
  17. Fazeli MS, Khaychuk V, Wittstock K, et al. Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognostic factors, and treatment landscape. Clin Exp Rheumatol. 2021; 39(5): 1108–1118.
  18. Kondoh Y, Makino S, Ogura T, et al. joint committee of Japanese Respiratory Society and Japan College of Rheumatology. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig. 2021; 59(6): 709–740.
  19. Yamakawa H, Ogura T, Kameda H, et al. Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). J Clin Med. 2021; 10(17).
  20. England BR, Hershberger D. Management issues in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol. 2020; 32(3): 255–263.
  21. Khanna D, Lescoat A, Roofeh D, et al. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. Arthritis Rheumatol. 2022; 74(1): 13–27.
  22. Vonk MC, Smith V, Sfikakis PP, et al. Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. Autoimmun Rev. 2021; 20(12): 102978.
  23. Basuita M, Fidler LM. Myositis Antibodies and Interstitial Lung Disease. J Appl Lab Med. 2022; 7(1): 240–258.
  24. Wu W, Guo Li, Fu Y, et al. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Clin Rev Allergy Immunol. 2021; 60(2): 293–304.
  25. Nannini C, Jebakumar AJ, Crowson CS, et al. Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open. 2013; 3(11): e003569.
  26. Lee AS, Scofield RH, Hammitt KM, et al. Consensus Expert Panel (CEP) Members. Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's. Chest. 2021; 159(2): 683–698.
  27. Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020; 79(1): 3–18.
  28. Koo SM, Uh ST. Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view. Korean J Intern Med. 2017; 32(4): 600–610.